Key Drivers
- High Gross Margin
- Liquidity Strength
- Leverage Pressure
AIAI Summary
SNDX is shifting into a real commercial story, with 92% revenue growth and 96% gross margins supporting a stronger long-term thesis, but the stock likely won't re-rate until management proves revenue can outgrow heavy operating spend, negative free cash flow, and rising dilution/leverage.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High Gross Margin
- •Liquidity Strength
- •Leverage Pressure
SNDX has strong product economics and improving losses/liquidity, but persistent cash burn, rising debt, and a stretched valuation keep the investment case risky.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •19 Support
- •Weak rebound
Over the last month, SNDX remains in a short-term downtrend with repeated support near $19.00-$19.10, but it needs a move back above $20.50-$21.00 to signal a meaningful reversal.
Brief rebound to $20.40 on 2026-08-07 after the late-July pullback
Sentiment & News
Key News Insights:
- •Revenue growth
- •Pipeline catalysts
- •Earnings miss
Syndax posted strong revenue growth and pipeline progress in Q2, but a wider-than-expected loss keeps the outlook balanced ahead of several key clinical catalysts.
The update is modestly positive for the stock as commercial momentum and upcoming data readouts offset the quarterly earnings miss
Similar Companies in Healthcare
Other companies in the same sector with AI ratings